Sapan Ghai, CCO at Sovereign Metals, discusses their superior graphite test results. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSENS.L Share News (SENS)

  • There is currently no data for SENS

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET CLOSE: Stocks waver as IMF cuts global growth forecast

Tue, 19th Apr 2022 17:06

(Alliance News) - Stocks in London ended lower on Tuesday, following the long Easter weekend, after the IMF warned Russia's invasion of Ukraine will weigh heavily upon global economic growth.

The new forecast now pointed to global economic growth at 3.6% for 2022. That is another drastic reduction in the outlook, primarily due to unprecedented economic pressures. Already in January, the IMF had lowered its global economic forecast for 2022 by half a percentage point, to 4.4%.

The world was already facing inflation problems, on the one side due to loose monetary policy in many wealthy nations, on the other due to supply snarls exacerbated by lingering effects of the pandemic.

Russia's invasion worsened the situation because both it and Ukraine are responsible for major commodity supplies of food and fuel. Much of what Ukraine exports is now inaccessible due to the invasion and much of what Russia sells is off limits due to sanctions set up to punish it for the attack.

The FTSE 100 index ended down 15.10 points, or 0.2%, at 7,601.28. The mid-cap FTSE 250 index lost 159.44 points, or 0.8%, at 20,962.17. The AIM All-Share index closed down 4.16 points, or 0.4%. at 1,056.00.

The Cboe UK 100 index ended down 0.1% at 757.59. The Cboe 250 closed down 0.6% at 18,457.77, and the Cboe Small Companies lost 0.5% at 15,349.55.

In mainland Europe, the CAC 40 stock index in Paris shed 0.8%, while the DAX 40 in Frankfurt ended 0.1% lower.

"European markets have got off to a lacklustre start to the week, pulling off their lows of the day, despite the IMF following the World Bank yesterday, in downgrading its outlook for the global economy," said CMC Markets analyst Michael Hewson.

In the FTSE 100, oil majors Shell and BP ended up 1.6% and 0.4% respectively, tracking spot oil prices higher.

Brent oil was quoted at USD107.80 a barrel at the London equities close, up from USD107.52 at the same time on Thursday.

At the other end of the large-caps, ITV closed down 3.6% after Berenberg downgraded the broadcaster to 'sell' from 'hold'.

In the FTSE 250, Spectris ended up 4.7% after unveiling a GBP300 million share buyback programme alongside the sale of its Omega Engineering subsidiary to Arcline Investment Management.

The precision instrumentation and controls supplier will net USD525 million from the Omega disposal. Specialist sensors provider Omega generated sales of GBP129.0 million in 2021 and adjusted earnings before interest, tax, depreciation and amortisation of GBP19.7 million.

The buyback will consist of an initial GBP150 million, "to be launched shortly", before a further GBP150 million tranche. The second instalment is subject to shareholder approval at the firm's annual general meeting on May 27.

At the bottom of the mid-caps, JTC lost 12% despite hiking its dividend after revenue and profit growth in 2021, with acquisitions helping to boost the fund manager's performance.

Revenue for 2021 grew 28% to GBP147.5 million from GBP115.1 million in 2020, and pretax profit jumped to GBP27.8 million from GBP11.2 million. Annualised new business wins totalled GBP20.9 million, up from GBP17.9 million in 2020.

The revenue growth reflected strong net organic growth of 9.6% plus inorganic growth of 19%, the firm said. JTC has been pleased with the integration and business performance of recent acquisitions, with all seven "on track", it said.

SSP closed down 6.3% after Deutsche Bank cut the food and beverage concessions operator to 'hold' from 'buy'.

Elsewhere, Sensyne Health plunged 34% after the clinical artificial intelligence company proposed delisting from London's AIM junior market.

The company is seeking approval from its shareholders for the delisting of the shares, in accordance with AIM rules, Sensyne Health explained. It will hold a general meeting on May 20.

The dollar was higher across the board in the wake of hawkish comments from St Louis Federal Reserve President James Bullard, who said a 75 basis point US interest rate hike should not be ruled out, Bloomberg reported.

Bullard, in a virtual conference held by the Council on Foreign Relations think tank, said the Fed would need to move decisively as it eyes lifting interest rates to around 3.5% this year.

Moreover, Bullard noted a hike of more than 50 basis points at a single policy meeting is not his "base case at this point", however. "I wouldn't rule it out, but it is not my base case here," he explained.

The next meeting of the policy-making Federal Open Market Committee is on May 4.

The pound was quoted at USD1.2997 at the London equities close, down from USD1.3060 at the close on Thursday.

The euro stood at USD1.0785 at the European equities close, lower against USD1.0797.

Against the yen, the dollar was trading at JPY128.77, up sharply from JPY125.91 late Thursday. The buck hit an intraday high of USD128.92 - its highest level since May 2002.

New York was higher at the London equities close weighing mixed earnings and a weakening global growth outlook against bargain-hunting tendencies following recent losses.

The DJIA was up 1.1%, the S&P 500 index up 1.3% and the Nasdaq Composite up 1.6%.

On Wall Street, Johnson & Johnson was the best Dow performer, up 4.0%. The drugmaker reported a drop in first-quarter earnings, despite sales growth of 5%.

The New Brunswick, New Jersey-based firm said earnings fell 17% to USD5.15 billion in the first three months of 2022 from USD6.20 billion a year previous. Per share, earnings dropped to USD1.93 from USD2.32, also representing a 17% fall.

Sales rose 5.0% to USD23.43 billion from USD22.32 billion. In Consumer Health, sales declined 1.5%, but in Pharmaceuticals, sales grew 6.3%.

The company hiked its quarterly dividend by 6.6% to USD1.13 per share from USD1.06.

Streaming services provider and content producer Netflix will report first-quarter earnings after the closing bell.

Gold stood at USD1,953.33 an ounce at the London equities close, lower against USD1,964.54 late Thursday.

The economic events calendar on Wednesday has Germany producer prices at 0700 BST.

The UK corporate on Wednesday has trading statements from distribution company Bunzl, gambling firm 888 Holdings and gold miner Centamin.

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
7 May 2021 19:23

IN BRIEF: Sensyne Health gets UK heath regulator boost

IN BRIEF: Sensyne Health gets UK heath regulator boost

Read more
7 May 2021 08:55

Sensyne's 'MagnifEye' gets MHRA special use authorisation

(Sharecast News) - Clinical artificial intelligence (AI) company Sensyne Health announced on Friday that its 'MagnifEye' software application, which uses AI to automate the accurate reading and analysis of lateral flow diagnostic tests, has been granted special use authorisation by the Medicines and Healthcare products Regulatory Agency (MHRA).

Read more
30 Apr 2021 14:45

Sensyne Health signs research deal with another NHS trust

(Sharecast News) - Clinical artificial intelligence (AI) company Sensyne Health has signed a five-year non-exclusive strategic research agreement (SRA) with the Royal Devon and Exeter NHS Foundation Trust, it announced on Friday.

Read more
30 Apr 2021 14:15

TRADING UPDATES: Henry Boot gets planning boost; Beximco sales jump

TRADING UPDATES: Henry Boot gets planning boost; Beximco sales jump

Read more
12 Mar 2021 13:03

IN BRIEF: Sensyne signs deal with UK government to fund Covid tests

IN BRIEF: Sensyne signs deal with UK government to fund Covid tests

Read more
12 Mar 2021 09:23

Sensyne signs £0.5m Covid-19 test deal with DHSC

(Sharecast News) - Clinical artificial intelligence (AI) technology company Sensyne Health has signed a £0.47m agreement with the Department of Health and Social Care, it announced on Friday, to conduct the second stage of a pilot study of its 'MagnifEye' technology for use with Covid-19 lateral flow diagnostic tests.

Read more
1 Mar 2021 16:41

EXECUTIVE CHANGES: New CFOs for Sensyne, Focusrite, Bango, 4D Pharma

EXECUTIVE CHANGES: New CFOs for Sensyne, Focusrite, Bango, 4D Pharma

Read more
1 Mar 2021 15:36

Sensyne Health gets UK approval for 'SYNE-COV' algorithm

(Sharecast News) - Clinical artificial intelligence (AI) company Sensyne Health announced on Monday that its 'SYNE-COV' machine learning algorithm for Covid-19 risk prediction has achieved regulatory approval for use in the UK.

Read more
1 Mar 2021 15:34

TRADING UPDATES: 1Spatial expects full-year results ahead of forecasts

TRADING UPDATES: 1Spatial expects full-year results ahead of forecasts

Read more
9 Feb 2021 14:43

Sensyne Health signs licence agreement with Excalibur

(Sharecast News) - Clinical artificial intelligence (AI) company Sensyne Health has signed an exclusive licence and development agreement with Excalibur Healthcare Services, it announced on Tuesday, to apply Sensyne's 'MagnifEye' system for use with Excalibur's proprietary lateral flow rapid diagnostic tests across a range of indications, including its Covid-19 antigen test currently being marketed in the UK and Europe.

Read more
9 Feb 2021 11:18

TRADING UPDATES: Northbridge, discoverIE And Tandem Outlook Upbeat

TRADING UPDATES: Northbridge, discoverIE And Tandem Outlook Upbeat

Read more
5 Feb 2021 12:28

EXECUTIVE CHANGES: Iconic Labs CEO; Tiziana Hires Executive Director

EXECUTIVE CHANGES: Iconic Labs CEO; Tiziana Hires Executive Director

Read more
3 Feb 2021 11:07

IN BRIEF: Sensyne Health Launches AI Algorithm For Patient Management

IN BRIEF: Sensyne Health Launches AI Algorithm For Patient Management

Read more
21 Jan 2021 11:32

Sensyne Health Interim Loss Widens But Boasts Of Commercial Progress

Sensyne Health Interim Loss Widens But Boasts Of Commercial Progress

Read more
20 Jan 2021 19:18

IN BRIEF: Sensyne Health Signs Long-Term Deal With NHS Trust

IN BRIEF: Sensyne Health Signs Long-Term Deal With NHS Trust

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.